Kaiser, Aetna, and Matrix settlements pushed Medicare Advantage fraud enforcement past $700 million this year, and three legal questions remain unanswered. Attorneys from Whistleblower Partners and WilmerHale weigh in on what survives the pleading stage, failure-to-delete liability, and whether Star Ratings enforcement is next.
Why this matters now
Risk adjustment enforcement keeps gathering speed. Kaiser Permanente affiliates paid $556 million in January, the largest False Claims Act settlement tied to Medicare Advantage risk adjustment on record. Aetna paid $117.7 million in March. In June, Matrix Medical Network, HealthFair, and HealthFair's founder agreed to pay a combined $56.5 million over invalid diagnosis codes submitted for risk adjustment. Behind the settlements, CMS now audits every eligible MA contract on a quarterly cadence, and the Department of Justice has named Medicare Advantage fraud its top enforcement priority.
The settlements answer one question: enforcement is here to stay. Three harder questions remain open. Their answers will shape defense strategy, reserve planning, and compliance budgets for every plan. Here is where each one stands.
Question 1: Which fact patterns survive the pleading stage?
Not every qui tam complaint becomes a nine-figure settlement. Courts dismiss FCA cases when relators fail to plead fraud with particularity, and the difference between a dismissed complaint and an intervened case often comes down to the fact pattern. Recent settlements point to the themes regulators find credible: retrospective chart reviews used to add revenue-generating codes, in-home assessments producing diagnoses no treating physician confirms, and addenda processes without clinical support. Risk adjustment leaders need a clear read on which of their own programs resemble the patterns gaining traction and which concerns are noise.
“The strongest risk-adjustment cases do more than identify unsupported codes: they expose a repeatable process for generating or retaining unsupported diagnoses, together with evidence that the organization knew what was happening,” said Ari Yampolsky, partner at Whistleblower Partners LLP. “At RISE West, we’ll discuss what separates those cases from allegations that do not survive scrutiny.”
Question 2: When does failing to delete a code become its own violation?
The Kaiser and Aetna matters share a thread. In both, the government alleged the organizations identified unsupported diagnoses and left them in place. The theory treats failure to delete as liability separate from the act of submission. If the theory holds, every plan running retrospective reviews inherits an obligation to act on what those reviews find. How far the obligation reaches, and how courts treat plans making good-faith corrections, remains unsettled. For compliance officers, this is the question with the most direct operational consequences.
“The Government appears to take the view that a risk-adjusting code not confirmed in a chart review necessarily gives rise to an obligation to submit a deletion,” said Brian Boynton, partner at WilmerHale. “We’ll examine the Government’s position and the contrary view,” he said of the panel’s plans for RISE West.
Question 3: Will enforcement expand into Star Ratings?
Attorneys tracking the docket see Stars as a logical next target. Quality bonus payments move billions of dollars each year, and the DOJ False Claims Act Working Group has already flagged network adequacy and access to care. A Stars case would look different from a coding case, and no one has fully mapped what a credible one requires at the pleading stage. Quality leaders who viewed FCA exposure as a risk adjustment problem now share the risk surface.
“Given the centrality of Stars ratings to MAOs’ business models – as reflected in the multiple suits filed by carriers challenging CMS Stars ratings determinations – and the tremendous volume of federal dollars that flow through it, Stars metrics fraud seems like a natural next target for future OIG and DOJ investigations," said Jason Silberberg, partner at Frier Levitt. "At RISE West, we’ll analyze the various challenges facing payors and providers who receive Stars-quality-based compensation in avoiding such investigations, and some of the unique difficulties in prosecuting such cases."
Hear the answers at RISE West
These three questions anchor an Extended Insight Session at RISE West: "RA Litigation Today: What Lawyers Say About Risk, Enforcement, and Exposure." Yampolsky, Boynton, and Jason Silberberg, Partner at Frier Levitt, bring all three perspectives to one stage: the relator's counsel, the defense bar, and the provider side. Over a full hour they will break down recent FCA settlements, DOJ priorities, and OIG audit trends, then take your questions in a live Q&A.